Last reviewed · How we verify
Inactivated vaccine booster
This inactivated vaccine booster works by stimulating the body's immune system to produce a specific response against a particular pathogen.
This inactivated vaccine booster works by stimulating the body's immune system to produce a specific response against a particular pathogen. Used for Prevention of COVID-19.
At a glance
| Generic name | Inactivated vaccine booster |
|---|---|
| Also known as | CoronaVac |
| Sponsor | Universidad del Desarrollo |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
The vaccine contains inactivated forms of a pathogen, which are unable to cause disease but still trigger an immune response. This response helps the body to recognize and fight off future infections.
Approved indications
- Prevention of COVID-19
Common side effects
- Pain, redness, or swelling at the injection site
Key clinical trials
- Extended Dosing Intervals Trial for Oral Cholera Vaccine, Kenya (PHASE4)
- COVID-19 Booster and IIV Schedule in Immunocompromised Hosts (PHASE2)
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
- Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults (PHASE3)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Autologous Dendritic Cell Vaccine in HIV1 Infection (PHASE1, PHASE2)
- Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inactivated vaccine booster CI brief — competitive landscape report
- Inactivated vaccine booster updates RSS · CI watch RSS
- Universidad del Desarrollo portfolio CI